Rabies

Bavarian Nordic Reports Additional Positive Phase 2 Results for its COVID-19 Vaccine Candidate Ahead of Phase 3 Trial

Retrieved on: 
Monday, February 28, 2022
Licensure, RNA transfection, Omicron, Rabies, Tick-borne encephalitis, Immune system, OMX, COVID-19, Janssen Pharmaceuticals, Smallpox vaccine, Adenoviridae, Johnson & Johnson, Monkeypox, Vaccine, Alpha, Severe acute respiratory syndrome coronavirus 2, ExpreS2ion Biotechnologies, FDA, Forward-looking statement, Technology, Goal, CEO, Vaccination, Government, Time, Bavarian Nordic

While the 50 g dose has shown positive results, it has been decided to use the 100 g dose in the Phase 3 trial to maximize the likelihood of success.

Key Points: 
  • While the 50 g dose has shown positive results, it has been decided to use the 100 g dose in the Phase 3 trial to maximize the likelihood of success.
  • Based on these encouraging results, Bavarian Nordic continues its preparations to initiate a Phase 3 trial in the first half of 2022.
  • Bavarian Nordic has licensed the global commercialization rights to the vaccine and has assumed the responsibility for further clinical development towards licensure.
  • Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines.

Ocugen, Inc. Announces U.S. FDA Lifts Clinical Hold on the Submission of Its Investigational New Drug Application for Its COVID-19 Vaccine Candidate COVAXIN™ (BBV152)

Retrieved on: 
Friday, February 18, 2022
NASDAQ, Private Securities Litigation Reform Act, GSK, Patient, Food, EUA, ICMR, Typhoid fever, Indian Council of Medical Research, Bharat Biotech, Diabetic retinopathy, Risk, NIV, SEC, Rabies, U.S. Securities and Exchange Commission, Review, Vaccine, World, BBV152, Security (finance), Chemistry, IND, COVAXIN, Clinical trial, Health Canada, Safety, Regulation of tobacco by the U.S. Food and Drug Administration, Therapy, Medical research, National Institute of Virology, WHO, FDA, Publication, Board, Acquisition, Research, Retina, BLA, World Health Organization, COVID-19, Vaccination, GLOBE, National Institute, Pharmaceutical industry, GlaxoSmithKline, Rotavirus, Chikungunya, Zika fever

COVAXIN is a whole-virion inactivated COVID-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades.

Key Points: 
  • COVAXIN is a whole-virion inactivated COVID-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades.
  • COVAXIN (BBVI52) is an investigational vaccine candidate product in the U.S.
  • It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) National Institute of Virology (NIV).
  • COVAXIN is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.

Ocugen/Harris Poll Finds Americans Want More COVID-19 Vaccine Options

Retrieved on: 
Tuesday, February 15, 2022
Health, Private Securities Litigation Reform Act, GSK, Patient, The Harris Poll, Food, EUA, CEO, Typhoid fever, Diabetic retinopathy, Bharat Biotech, Risk, Diphtheria, Public relations, Parent, SEC, Rabies, Emory University, U.S. Securities and Exchange Commission, Vaccine, World, Security (finance), Chemistry, COVAXIN, Clinical trial, Adult, Safety, Health Canada, Regulation of tobacco by the U.S. Food and Drug Administration, WHO, LinkedIn, Twitter, FDA, Publication, Child, Acquisition, Chickenpox, Public opinion, Research, Mumps, Retina, World Health Organization, BLA, COVID-19, Probability, Vaccination, Face, GLOBE, Pharmaceutical industry, GlaxoSmithKline, Rotavirus, Chikungunya, Zika fever

Ocugen, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19.

Key Points: 
  • Ocugen, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19.
  • We are co-developing Bharat Biotechs COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.
  • The acquisition of the rabies vaccine facility, Chiron Behring, from GlaxoSmithKline (GSK) has positioned Bharat Biotech as the world's largest rabies vaccine manufacturer.
  • Any forward-looking statements that we make in this press release speak only as of the date of this press release.

Bavarian Nordic Announces Breakthrough Therapy Designation for its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults

Retrieved on: 
Monday, February 14, 2022
RSV, Smallpox vaccine, Food, OMX, Tick-borne encephalitis, Bronchiolitis, CEO, Risk, Company, Volunteering, Forward-looking statement, Review, Death, Licensure, Infection, Immunity, Vaccine, Smallpox, Immune system, Adult, Goal, Immunodeficiency, Regulation of tobacco by the U.S. Food and Drug Administration, Urinary tract infection, Antigen, Rabies, FDA, Pneumonia, Ageing, Government, Disease, Viral load, Respiratory syncytial virus, Monkeypox, Formica, Johnson & Johnson, COVID-19, Vaccination, The New England Journal of Medicine, Janssen Pharmaceuticals, Pharmaceutical industry, Bavarian Nordic

A Breakthrough Therapy Designation is designed to expedite the development and regulatory review of medicines that are intended to treat a serious condition.

Key Points: 
  • A Breakthrough Therapy Designation is designed to expedite the development and regulatory review of medicines that are intended to treat a serious condition.
  • The designation provides an option to work more closely with FDA for the development and review of MVA-BN RSV.
  • MVA-BN RSV, Bavarian Nordic's vaccine candidate for the prevention of RSV, is being developed for use in elderly individuals.
  • The MVA-BN RSV vaccine demonstrated a vaccine efficacy of up to 79% in preventing symptomatic RSV infections3.

Alley Cat Rescue 2021 Global Feral Fix Challenge Leads to Spay/Neuter of Over 45,000 Community Cats

Retrieved on: 
Wednesday, February 2, 2022
Euthanasia, Cat, TNR, Starvation, Sterilization, Alley Cat Rescue, ACR, United Arab Emirates, Vaccination, Population, Disease, Challenge, Veterinarian, Rabies, Veterinary medicine, Hunting

RAINIER, Md., Feb. 2, 2022 /PRNewswire-PRWeb/ --Alley Cat Rescue's 11th annual Feral Fix Challenge wrapped up on December 31, 2021.

Key Points: 
  • RAINIER, Md., Feb. 2, 2022 /PRNewswire-PRWeb/ --Alley Cat Rescue's 11th annual Feral Fix Challenge wrapped up on December 31, 2021.
  • The Challenge is a global event that invites veterinarians to get involved with trap-neuter-return (TNR) by providing low-cost or free spay/neuter and rabies vaccination for free-roaming cats.
  • The goal of the Challenge is to save feral cats from shelter euthanasia, starvation, and disease by humane population management.
  • Alley Cat Rescue is a national nonprofit organization dedicated to the welfare of all cats: domestic, stray, abandoned, and feral.

Molecular Targeting Technologies, Inc., Thomas Jefferson University and North China Pharmaceutical Co., Ltd Announced the Chinese Approval for a Rabies Drug

Retrieved on: 
Wednesday, January 26, 2022
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Conference, Faculty, Commerce, Rabies, Death, Evans Blue, Science, Industry, WHO, National, TJU, Partnership, Patient, Thomas Jefferson University, Professor, NMPA, Textile, Radiopharmaceutical, Student, Medicine, Research, R, Post-exposure prophylaxis, NCPC, Pharmacy, Rabies virus, Technology, Doctor of Philosophy, Architecture, Chinese, Safety, Health, EB, CEO, Cancer, Vaccine, Pharmaceutical industry, PRC, Engineering

Molecular Targeting Technologies, Inc., (MTTI) announced that the Chinese NMPA has approved a rabies virus neutralizing, fully human antibody, Ormutivimab for post-exposure prophylaxis.

Key Points: 
  • Molecular Targeting Technologies, Inc., (MTTI) announced that the Chinese NMPA has approved a rabies virus neutralizing, fully human antibody, Ormutivimab for post-exposure prophylaxis.
  • Ormutivimab was invented at Thomas Jefferson University and licensed to MTTI which has conducted trials in China in partnership with the North China Pharmaceutical Co., Ltd (NCPC).
  • Rose Ritts, PhD, Executive Vice President and Chief Innovation Officer for Jefferson Health & Thomas Jefferson University notes, Jefferson is excited to see Ormutivimab gain approval.
  • North China Pharmaceutical Group New Drug Research & Development Co., Ltd. (NCPC R&D) is a wholly owned subsidiary of NCPC located in Shijiazhuang, Hebei Province, PRC.

LIVISTO launches self-care platform for veterinarians HappyVetProject

Retrieved on: 
Tuesday, January 18, 2022
American Veterinary Medical Association, Human, AVMA, Veterinarian, Zoonosis, Suicide, Degenerative disease, Mental health, Health, Animal, Anxiety, Veterinary medicine, Social support, Depression, Rabies, Multimedia, Risk, Frustration, Compassion fatigue, Tuberculosis, Public relations

BARCELONA, Spain, Jan. 18, 2022 /PRNewswire/ -- Aware of the need for proactive mental health self-management by veterinary professionals, HappyVetProject aims to provide a platform for practitioners with its website www.happyvetproject.org (@happyvetproject), a digital platform with a variety of content where veterinarians will find personalized self-care formulas to counteract the stress derived from their profession.

Key Points: 
  • BARCELONA, Spain, Jan. 18, 2022 /PRNewswire/ -- Aware of the need for proactive mental health self-management by veterinary professionals, HappyVetProject aims to provide a platform for practitioners with its website www.happyvetproject.org (@happyvetproject), a digital platform with a variety of content where veterinarians will find personalized self-care formulas to counteract the stress derived from their profession.
  • HappyVetProject is a LIVISTO initiative (#AlongWithYou).
  • According to a study by the American Veterinary Medical Association (AVMA), carried out on 12,000 veterinarians in the U.S. from 1979 to 2015, veterinarians are 3.5 times more likely to commit suicide than the general population.
  • HappyVetProject believes there is insufficient social recognition of the work of veterinary professionals.

COVAXIN™ (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety

Retrieved on: 
Saturday, January 8, 2022
Vaccine, COVID-19, BLA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, National Institute of Virology, Therapy, Chemistry, NIV, Indian Council of Medical Research, Typhoid fever, Security (finance), Rabies, NASDAQ, GSK, SEC, FDA, MPH, WHO, Medical research, Death, Time, Diabetic retinopathy, COVAXIN, Research, Vaccination, Publication, ICMR, Bharat Biotech, National Institute, Drug, BBV152, Clinical trial, Safety, Hospital, Food, Patient, CMI, CEO, Health Canada, Private Securities Litigation Reform Act, World, Entrepreneurship, GLOBE, Associate, Risk, EUA, Retina, U.S. Securities and Exchange Commission, Acquisition, Adult, MedRxiv, World Health Organization, Pharmaceutical industry, Chikungunya, Rotavirus, GlaxoSmithKline, Alpha, MD, Delta, Zika fever

The analysis found that participants receiving a booster dose saw a significant increase in neutralizing titers, an important predictor of vaccine efficacy.

Key Points: 
  • The analysis found that participants receiving a booster dose saw a significant increase in neutralizing titers, an important predictor of vaccine efficacy.
  • These booster data provide critical information about how COVAXIN can be used in the ongoing battle against COVID-19.
  • We are encouraged by these results which continue to suggest that COVAXIN remains an important, broad-spectrum vaccine candidate with durability.
  • Additional data from the analysis found that more than 75 percent of all participants had a detectible neutralizing antibody response six months post their second dose of COVAXIN.

Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base

Retrieved on: 
Monday, December 6, 2021
Volunteering, OMX, Smallpox vaccine, CEO, Forward-looking statement, Death, Company, Janssen Pharmaceuticals, Hospital, Viral load, Immunodeficiency, Antigen, USD, Johnson & Johnson, Ageing, COVID-19, Vaccine, Vaccination, Tick-borne encephalitis, Goal, USA, CET, Immunity, Smallpox, Adult, Infection, Participation, Bronchiolitis, Pneumonia, Q&A, The New England Journal of Medicine, Government, RSV, Monkeypox, FDA, Rabies, Immune system, Formica, Citigroup, Urinary tract infection, Pharmaceutical industry

Bavarian Nordic intends to fund the trial through an equity raise, of up to 10% of its registered share capital.

Key Points: 
  • Bavarian Nordic intends to fund the trial through an equity raise, of up to 10% of its registered share capital.
  • Paul Chaplin, President and CEO of Bavarian Nordic, commented: The progress of our COVID-19 vaccine has further de-risked the profile of Bavarian Nordic and allows us to make important strategic decisions with respect to our promising RSV vaccine candidate.
  • Bavarian Nordic has engaged a contract research organization and expects to initiate a pivotal RSV Phase 3 trial in the first half of 2022.
  • Bavarian Nordic plans to finance this through an equity capital raise of up to 10% of its registered share capital.

Bavarian Nordic Reports Positive Topline Phase 2 Results for its COVID-19 Vaccine Candidate

Retrieved on: 
Sunday, December 5, 2021
Volunteering, OMX, Smallpox vaccine, CEO, Technology, Forward-looking statement, Janssen Pharmaceuticals, Alpha, Severe acute respiratory syndrome coronavirus 2, Johnson & Johnson, Vaccine, Vaccination, COVID-19, Tick-borne encephalitis, Goal, USA, CET, Immunity, Adult, Participation, Q&A, Government, RNA transfection, Monkeypox, Antibody, FDA, Rabies, Licensure, Immune system, ExpreS2ion Biotechnologies, Pharmaceutical industry

Paul Chaplin, President and CEO of Bavarian Nordic, commented: We are very pleased to report positive top-line results for our COVID-19 vaccine candidate, confirming the perfect profile as a non-adjuvanted universal booster vaccine.

Key Points: 
  • Paul Chaplin, President and CEO of Bavarian Nordic, commented: We are very pleased to report positive top-line results for our COVID-19 vaccine candidate, confirming the perfect profile as a non-adjuvanted universal booster vaccine.
  • These results highlight the urgent need for an improved vaccine providing a more robust and long-lived level of protection.
  • ABNCoV2 is a next-generation COVID-19 vaccine candidate, initially developed by AdaptVac using their proprietary capsid virus like particle (cVLP) technology.
  • Bavarian Nordic has licensed the global commercialization rights to the vaccine and has assumed the responsibility for further clinical development towards licensure.